115 Participants Needed

Proton Craniospinal Radiation for Cancer in the Brain and Spinal Cord

Recruiting at 7 trial locations
JY
Overseen ByJonathan Yang
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: NRG Oncology
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.

Who Is on the Research Team?

JT

Jonathan T Yang

Principal Investigator

NRG

Are You a Good Fit for This Trial?

This trial is for adults with breast cancer or non-small cell lung cancer that has spread to the fluid around the brain and spinal cord. Participants must have a confirmed diagnosis, positive cerebrospinal fluid (CSF) cytology for malignancy, and be suitable candidates for radiation therapy.

Inclusion Criteria

I have not yet registered for Step 1.
My spinal fluid test shows cancer cells.
I have been diagnosed with breast cancer or NSCLC through a biopsy.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Treatment

Patients undergo either involved-field radiation therapy (IFRT) or proton craniospinal irradiation (pCSI) 5 days a week for a total of 10 days

2 weeks
10 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 months
Every 3 months

Long-term Follow-up

Participants continue to be monitored for overall survival and other outcomes

Up to 3 years
Every 6 months

What Are the Treatments Tested in This Trial?

Interventions

  • Involved-Field Radiation Therapy
  • Proton Beam Craniospinal Irradiation
Trial Overview The RADIATE-LM Trial compares proton craniospinal irradiation (pCSI), which targets the entire central nervous system more accurately, against involved-field radiation therapy (IFRT), which treats specific areas of leptomeningeal metastasis using x-rays.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm 2 (pCSI)Experimental Treatment7 Interventions
Group II: Arm 1 (IFRT)Active Control7 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

NRG Oncology

Lead Sponsor

Trials
242
Recruited
105,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security